Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880745 | 0.83 | DNMT1 (0.41) | DNMT1ALDH1A1MAPK1 | |
| SCHEMBL5880867 | 0.79 | LMNA (0.39) | DNMT1ALDH1A1MAPK1 | |
| SCHEMBL7998562 | 0.76 | DNMT1 (0.38) | DNMT1 | |
| SCHEMBL5880727 | 0.76 | BCHE (0.42) | DNMT1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL5880792 | 0.75 | KMT2A (0.38) | DNMT1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL8007831 | 0.75 | DNMT1 (0.38) | DNMT1ALDH1A1 | |
| SCHEMBL7999810 | 0.74 | DNMT1 (0.38) | DNMT1 | |
| SCHEMBL5880739 | 0.74 | ALDH1A1 (0.38) | DNMT1ALDH1A1 | |
| SCHEMBL5880825 | 0.73 | DNMT1 (0.38) | DNMT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8008848 | 0.72 | PTGDR2 (0.43) | DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | DNMT1 742/4885ALDH1A1 729/4885MAPK1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.